← All trials
NCT07089329
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2025
- Primary completion
- Sep 30, 2025
- Completion date
- Oct 1, 2025
- First posted
- Jul 28, 2025
- Last posted
- Jul 28, 2025
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universitas SriwijayaLead sponsor
- Dexa Medica GroupCollaborator
- Universitas SriwijayaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.